- The key vendors in the global hyperphosphatemia drugs market 2015-2019 are Sanorfi, Fresenius Medical Care, Shire.Keryx Biopharmaceuticals and Vifor Pharma
London, 03 August 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the global hyperphosphatemia drugs market 2015-2019. Vendors provide co-pay assistance to individuals who purchase medications for the treatment of hyperphosphatemia. These assistance programs by pharmaceutical companies allow individuals to buy branded drugs. The global hyperphosphatemia drugs market 2015-2019 is estimated to grow at a CAGR of 10.71% during 2014-2019.
“The global hyperphosphatemia drugs market is growing rapidly because of the high prevalence of CKDs among the population, resulting in a rise in the incidence of hyperphosphatemia among individuals,” says Faisal Ghaus, Vice President of Technavio Research.
“The company that manufactures and markets a drug that can effectively treat and cure hyperphosphatemia, in addition to exhibiting a high safety and efficacy profile, will likely gain a competitive edge over its peers.”
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
